Jason Haas

Jason Haas (board member) discloses dealings in 2 companies, chiefly Ligand Pharmaceuticals Inc and Syros Pharmaceuticals, Inc. Between 29 June 2022 and 12 August 2026, the trades on record add up to 12 filings.

On the open market, the record shows 1 purchase and 2 sales worth €1.8M. No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 4 share grants and 5 option exercises. In 2026 alone, the filings show no purchases and 1 sale.

The latest filing, published on 14 August 2026, reports an open-market sale of €1.8M in Ligand Pharmaceuticals Inc. The last insider purchase was made public on 12 September 2024, 766 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.